By Gilang Cahya 
The intricate dance of cellular development, a symphony of growth, expansion, and directed migration, is fundamental to the formation of every tissue and organ within a living organism. This precisely orchestrated process is governed by a complex network of intracellular pathways, intricate cascades of signaling molecules that meticulously regulate cellular behavior. A critical aspect of this regulation is the prevention of uncontrolled or non-programmed growth, which, if disrupted, can lead to severe developmental malformations or the unchecked proliferation characteristic of cancer. Among these vital regulatory pathways, the PTEN/PI3K axis stands out as a cornerstone, a delicate balance of chemical reactions essential for normal cellular function.
The PTEN/PI3K Axis: A Delicate Balance Thrown Off Kilter
At the heart of cellular growth and survival lies the PTEN/PI3K signaling pathway. PTEN (Phosphatase and Tensin homolog) acts as a tumor suppressor, effectively putting the brakes on cell growth and proliferation by counteracting the activity of PI3K (Phosphoinositide 3-kinase). PI3K, in contrast, promotes cell growth, survival, and metabolism. This finely tuned interplay ensures that cells divide and grow only when and where necessary.
However, this equilibrium is precarious. Mutations in the PTEN gene are a significant disruptor of this critical pathway. When PTEN is compromised, its ability to suppress PI3K is diminished, leading to the overactivation of PI3K. This imbalance can have far-reaching consequences, not only contributing to the development of various cancers, such as breast and prostate cancer, but also manifesting in a spectrum of developmental disorders when present in the germline – the cells that pass genetic information to offspring.
PTEN Hamartoma Tumour Syndrome (PHTS): A Complex and Heterogeneous Disorder
From a clinical perspective, germline mutations in PTEN give rise to a group of disorders collectively known as PTEN Hamartoma Tumour Syndrome (PHTS). PHTS is characterized by a remarkable degree of heterogeneity, meaning that individuals with the same genetic mutation can experience vastly different clinical manifestations. This variability makes diagnosis challenging and complicates the development of effective therapeutic strategies. The underlying cause of this clinical diversity has remained largely elusive, hindering the creation of robust preclinical models and the implementation of targeted molecular therapies.
A particularly concerning and prevalent feature of PHTS, especially in pediatric patients, is the development of vascular malformations. These are abnormal formations of blood vessels that can range in severity and impact. Scientific understanding has long pointed to the role of PI3K mutations in endothelial cells – the specialized cells that form the inner lining of blood vessels – as a trigger for such malformations. It is therefore not surprising that a significant proportion of PHTS patients, estimated to be as high as one in two, develop these vascular abnormalities during early childhood.
These vascular lesions can be accompanied by severe pain and swelling, significantly impacting a child’s quality of life. Current therapeutic approaches primarily involve surgical interventions and embolization, a procedure aimed at deliberately blocking the affected blood vessels to reduce blood flow and lesion size. However, the effectiveness and feasibility of these treatments are heavily dependent on the precise location and extent of the malformations. In many cases, these interventions may not be possible, leaving patients with limited or no viable therapeutic options. This unmet clinical need underscores the urgency for a deeper understanding of PHTS and the development of novel treatment strategies.
A Landmark Discovery: Uniparental Disomy as the Culprit
In a significant stride toward unraveling the genetic underpinnings of PHTS-related vascular malformations, researchers at the Josep Carreras Institute have identified a novel genetic mechanism responsible for these debilitating conditions. The Endothelial Pathobiology and Microenvironment group, under the leadership of Dr. Mariona Graupera and in collaboration with Dr. Sandra Castillo (formerly of the Josep Carreras Institute and now at SDJ Pediatric Cancer Center Barcelona) and Dr. Eulàlia Baselga (Head of the Pediatric Dermatology Unit at Hospital Sant Joan de Déu), has pinpointed a specific genetic alteration.
Through a rigorous and comprehensive analysis of tissue biopsies and patient-derived endothelial cells, the research team made a pivotal discovery. They found that individuals with PHTS often exhibit a phenomenon known as "uniparental disomy" affecting the PTEN gene. This means that instead of inheriting one functional copy of the PTEN gene from each parent, these patients have inherited two copies from one parent and none from the other. Crucially, in these cases, the inherited copy from one parent is non-functional. This effectively renders both copies of the PTEN gene inoperative, leading to the loss of its tumor-suppressive function and the subsequent overactivation of the PI3K pathway.
The implications of this discovery are profound. In a series of meticulously designed experiments using mouse models, the researchers were able to demonstrate that this specific genetic alteration – the replacement of a functional PTEN copy with a non-functional one via uniparental disomy – could indeed explain the majority of the vascular abnormalities observed in PHTS patients. This finding provides a crucial mechanistic link between a specific genetic event and a common, debilitating clinical manifestation of the syndrome.
A New Era of Research and Therapeutic Development
This groundbreaking genetic discovery, recently published in the prestigious scientific journal Cancer Discovery, a publication of the American Association for Cancer Research, has paved the way for unprecedented advancements in PHTS research. The identification of uniparental disomy as a key driver of vascular malformations has enabled the creation of the first accurate mouse model of PHTS-related vascular malformations. This preclinical model serves as an invaluable tool, a benchmark against which potential therapeutic interventions can be rigorously tested.
Utilizing this novel mouse model, the researchers explored the efficacy of two well-established anticancer drugs known to counteract PI3K activity, mimicking the role of a functional PTEN. These drugs, rapamycin and capivasertib, target downstream effectors in the PI3K signaling cascade. The studies revealed that both rapamycin and capivasertib significantly reduced vascular growth in the mouse model. This suggests that by inhibiting the downstream consequences of PI3K overactivation, these drugs can effectively mitigate the development of vascular malformations.
Interestingly, the research also found that directly inhibiting PI3K itself with the drug alpelisib did not yield substantial benefits in this context. This finding highlights the nuanced nature of the PTEN/PI3K pathway and suggests that targeting specific downstream components may be a more effective therapeutic strategy for PHTS-related vascular malformations.
Translating Discovery into Clinical Hope: Proof-of-Concept Treatment
The research team did not stop at preclinical findings. They have taken a crucial step in translating their discoveries into tangible clinical benefit by providing a proof-of-concept for the off-label use of rapamycin. Two patients diagnosed with PHTS, who were suffering from significant vascular overgrowth and associated pain, were treated with rapamycin. The results were remarkably promising: both patients exhibited a reduction in vascular overgrowth and, importantly, a complete abatement of their lesion-associated pain.
These positive outcomes represent a significant beacon of hope for patients and families affected by PHTS. The ability to intervene early in the disease process, before significant complications arise, could dramatically improve patients’ long-term survival and overall quality of life.
A Window for Early Diagnosis and Intervention
The implications of this research extend beyond therapeutic advancements. PHTS is often diagnosed late, particularly in adults, when cancerous growths have already developed. However, the presence of vascular malformations as a pediatric manifestation of PHTS offers a unique and critical clinical opportunity for early diagnosis. Identifying these vascular abnormalities in children could prompt genetic testing for PTEN mutations, leading to an earlier diagnosis of PHTS.
An early diagnosis is paramount for several reasons. It allows for proactive monitoring and management of potential health risks associated with PHTS, including an increased susceptibility to certain cancers. Furthermore, it opens the door for earlier intervention with therapies like rapamycin, potentially preventing or mitigating the severity of vascular malformations and their associated debilitating symptoms. This shift towards early detection and intervention could fundamentally change the trajectory of PHTS management, moving from reactive treatment of established disease to proactive prevention and management.
Funding and Future Directions
This pioneering research was made possible through the generous support of several key organizations. Funding was provided by the PTEN Research Foundation, the Spanish Ministry of Science, Innovation and Universities of Spain, and "la Caixa" Foundation. Their commitment to advancing scientific understanding of rare diseases has been instrumental in achieving these significant breakthroughs.
The discovery of uniparental disomy as a primary cause of PHTS-related vascular malformations, coupled with the promising results of rapamycin treatment, marks a pivotal moment in the fight against this complex syndrome. Future research will likely focus on further refining therapeutic strategies, exploring the long-term efficacy and safety of rapamycin and other PI3K-inhibiting agents, and investigating the broader spectrum of PHTS manifestations. Understanding the precise molecular mechanisms underlying the heterogeneity of PHTS will also be crucial for developing personalized treatment approaches. The development of more sophisticated preclinical models, building upon the success of the newly generated mouse model, will be vital for accelerating the discovery and validation of novel therapies. Ultimately, the goal is to translate these scientific advances into improved clinical outcomes, offering a brighter future for individuals affected by PTEN Hamartoma Tumour Syndrome.
